Literature DB >> 658615

Characteristics of human erythrocyte insulin receptors.

K K Gambhir, J A Archer, C J Bradley.   

Abstract

Highly specific insulin receptors have been identified on human erythrocytes. A modification of the monocyte insulin radioreceptor technique permitted distinct separation of human erythrocytes with their bound insulin from the free insulin. When incubated with 80 pg. per milliliter of 125I-insulin (pH 8.0, 3.5 hours, 15 degrees C.), erythrocytes from 17 normal volunteers specifically bound 10 per cent (+/- 1.450 S.D.) of the total 125I-insulin. Less than 15 per cent of the total 125I-insulin bound was nonspecific. Binding of 125I-insulin to human erythrocytes was dependent on pH and temperature. Less than 5 per cent of the insulin available to the plasma membrane was degraded. Both calcium and magnesium enhanced 125I-insulin binding by 100 per cent but had no synergistic effect when mixed in a 1:1 molar ratio. Scatchard analysis of the binding data resulted in a curvilinear plot with characteristics typical of negative cooperative interactions between receptor sites and with an unoccupied site affinity constant of 0.1 X 10(8) M-1. Human erythrocytes have 2,000 insulin binding sites per erythrocyte with 14 sites per square micrometer of surface area. The readily available human erythrocyte, thus, has both specific insulin binding sites and binding characteristics similar to other human cell types. These studies have provided the basis for further clinical investigation of polypeptide hormone receptors on human erythrocytes.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 658615     DOI: 10.2337/diab.27.7.701

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  55 in total

1.  Comparison of erythrocyte insulin receptors in different species of vertebrates.

Authors:  P Maćkowiak; L Nogowski; K W Nowak
Journal:  Naturwissenschaften       Date:  1992-09

2.  Changes in insulin receptor functions of the erythrocyte by treatment of non-insulin-dependent diabetes mellitus (NIDDM) patients with glibenclamide and diet control.

Authors:  V R Agarwal; A K Rastogi; C G Agarwal; P Sagar
Journal:  Acta Diabetol Lat       Date:  1986 Jul-Sep

3.  Potassium efflux: a simple method to determine intactness of erythrocytes.

Authors:  K K Gambhir; V R Agarwal
Journal:  J Natl Med Assoc       Date:  1990-08       Impact factor: 1.798

4.  Dynamics of nonspecific adsorption of insulin to erythrocyte membranes.

Authors:  R M Fulbright; D Axelrod
Journal:  J Fluoresc       Date:  1993-03       Impact factor: 2.217

5.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

6.  Insulin degradation in human erythrocyte: effects of cations.

Authors:  G Bellomo; P L Nicotera; F Travaglino; A Palma Martino; F Mirabelli; P Fratino
Journal:  Acta Diabetol Lat       Date:  1985 Jan-Mar

7.  Insulin degrading enzyme activity and insulin binding of erythrocytes in normal subjects and Type 2 (non-insulin-dependent) diabetic patients.

Authors:  E Standl; H J Kolb
Journal:  Diabetologia       Date:  1984-07       Impact factor: 10.122

8.  The effect of nitric oxide on glucose metabolism.

Authors:  Dalip Ragoobirsingh; Donovan McGrowder; Tara Dasgupta; Paul Brown
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

9.  Insulin effect in vitro on human erythrocyte plasma membrane.

Authors:  P Luly; P Baldini; S Incerpi; E Tria
Journal:  Experientia       Date:  1981-04-15

10.  Trial of sulfonylurea in combination with insulin in the therapy of diabetes type I and II. Evidence against a primary extrapancreatic receptor effect.

Authors:  W P Bieger; R Dlugosch; A Rettenmeier; H D Holler; H Bert; W Schwarz; W Fiehn; J Merkt; H Weicker
Journal:  Klin Wochenschr       Date:  1984-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.